Friday 24 August 2018

Entecavir Patent Evaluation, Molecular Modelling Study of Drug-Resistant HBV: (SJFN) - Lupine Publishers

Entecavir Patent Evaluation, Molecular Modelling Study of Drug-Resistant HBV by Krishnasarmapathy* in Scholarly Journal of Food and Nutrition (SJFN) in Lupine Publishers

Entecavir is an oral antiviral drug used in the treatment of hepatitis B infection. Entecavir is a guanosine nucleoside analogue with selective activity against hepatitis B virus (HBV), which inhibits reverse transcription, Hepatitis B virus (HBV) is highly endemic in South Africa and across sub-Saharan Africa, where around 8% of people are chronically infected, and rates of HBV-related liver cancer are some of the highest in the world. Globally, viral hepatitis causes approximately 1.3 million deaths every year-more than either malaria or tuberculosis-with around 240 million people chronically infected with HBV1. The currently available anti-HBV drugs show potent antiviral activity in patients with chronic hepatitis B; however, the resistance and cross-resistance to the drugs is a major obstacle in long-term treatment. Many studies have been conducted to understand the molecular basis of drug resistance, and the mechanistic characterization and molecular modeling of anti-HBV drugs complexed with HBV RT have been reported.

No comments:

Post a Comment

Note: only a member of this blog may post a comment.